Abstract | PURPOSE: EXPERIMENTAL DESIGN: Several cell lines, patient-derived tumor cells, and xenografts in severe combined immunodeficient mice were used to examine the anti-MCL and anti-CLL activity of edelfosine. Furthermore, we analyzed the mechanism of action and drug biodistribution of edelfosine in MCL and CLL tumor-bearing severe combined immunodeficient mice. RESULTS: CONCLUSIONS: Our data indicate that edelfosine accumulates and kills MCL and CLL cells in a rather selective way, and set coclustering of Fas/CD95 and lipid rafts as a new framework in MCL and CLL therapy. Our data support a selective antitumor action of edelfosine.
|
Authors | Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate, Ander Estella-Hermoso de Mendoza, Janny A Villa-Pulgarin, Mercè de Frias, Gaël Roué, Joan Gil, Dolors Colomer, Miguel A Campanero, Maria J Blanco-Prieto |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 16
Issue 7
Pg. 2046-54
(Apr 01 2010)
ISSN: 1557-3265 [Electronic] United States |
PMID | 20233887
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010 AACR. |
Chemical References |
- Antineoplastic Agents
- Phospholipid Ethers
- edelfosine
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Apoptosis
(drug effects)
- Cell Proliferation
(drug effects)
- Dose-Response Relationship, Drug
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, metabolism, pathology)
- Lymphoma, Mantle-Cell
(drug therapy, metabolism, pathology)
- Membrane Microdomains
(drug effects, metabolism)
- Mice
- Mice, Inbred C57BL
- Mice, SCID
- Phospholipid Ethers
(therapeutic use)
- Substrate Specificity
(drug effects)
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
|